No consistent pattern was seen for the four sites. The risk was slightly higher among the short-term nonusers
for rectum cancer (relative risk, 1.28) but this was not statistically significant (P = 0.8) and was not seen for other digestive tract sites.
Therefore, changes in medication status due to undiagnosed cancer do not explain our findings.